EMPEROR-Preserved was a double-blind trial that randomised 5,988 patients with class II-IV HF and an ejection fraction >40% (1:1) to the SGLT2 inhibitor empagliflozin (10 mg daily) or placebo, in addition to standard care. SGLT2 inhibitors are known to reduce the risk of HF hospitalisation in patients with HFrEF and currently there are limited pharmacological interventions with proven efficacy in HFpEF. The objective of EMPEROR-Preserved was therefore to assess the effects of SGLT2 inhibition on major outcomes in patients with HFpEF. This review is sponsored by an educational grant from Boehringer Ingelheim and Eli Lilly.
A free full-text PDF of the paper Anker S.D. et al Empagliflozin in Heart Failure with a Preserved Ejection Fraction: The EMPEROR-Preserved trial N Engl J Med. 2021;385(16):1451-1461 is available here.
Please login below to download this issue (PDF)